Bustos-Saldaña R, López-Hernández G, Bustos-Mora A, Bustos-Mora R, Pérez-Larios F, Salgado-Rodríguez M.

Language: Spanish
References: 25
Page: 10-13
PDF size: 54.53 Kb.

ABSTRACT

Objective: Our aim was to identify changes that demonstrate daily fasting glucose in a group of patients with diabetes. Design: We conducted a descriptive and cross-sectional study. Materials and methods: Results were obtained from 4,515 patients with diabetes who attended the Family Medicine Service at the Mexican Social Security Institute’s (IMSS) Family Medicine Service in Ciudad Guzmán, Jalisco, Mexico during 1 year (2003). Results: A total of 66% of patients were female; 31.9% were employed, and 31.5% were married. On the other hand, only 0.6% of patients had children, 23.7% had parents, 6.1% were retired, and 6.1% had relatives who were retired. General glucose average was 177.55 ± 76.1 mg/dl; general average in women was 182.79 ± 76.55 mg/dl, while in men it was 168.24 ± 72.96 mg/dl (p ‹ 0.00001). Results by weekday were as follows: Monday, 190.99 ± 76.48 mg/dl; Tuesday, 168.94 ± 74.65 mg/dl; Wednesday, 169.77% ± 73.55 mg/dl; Thursday, 174.05 ± 77.97 mg/dl, and Friday, 182.06 ± 74.45 mg/dl (p ‹0.000001). Conclusions: Patients had inadequate fasting glucose averages for metabolic control. Glucose results on Mondays were higher than on other days of the week. Women showed greater lack of control than men.

REFERENCES

1. Cowell JA. Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes 1996; 45 suppl 3: 387-90.

2. Davis TM, Millins H, Stratton IM, Holman RR, Turner RC. Risk factors for stroke in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999; 24; 159(10): 1097-103.

3. Edelman SV. Importance of glucose control. Med Clin North Am 1998; 82(4): 665-87.

4. Ginsberg BJ, Mazze R. Clinical consequences of the diabetes control and complications trial. N J Med 1994; 91(4): 221-4.

5. Keen H. The diabetes control and complications trial (DCCT). Health Trends 1994; 26(2): 41-43.

6. Nasr CE, Hoogwerf BJ, Faiman C, Reddy SS. United Kingdom Prospective Study (UKPDS). Effects of glucose and blood pressure control and complications of type 2 diabetes mellitus. Cleve Clin J Med 1999; 66(4): 247-53.

7. Florkowski CM, Scott RS. Type 2 diabetes towards the new millennium- the relative importance glycaemic versus lipid control. Aust NZ J Med 199; 29(2): 249-53.

8. Danne T, Weber B, Hartmann R, Enders Y, Burger W, Hovener G. Long-term glycemic control has nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. Diabetes Care 1994; 17(12): 1390-6.

9. Tattesall R. Targets of therapy or NIDDM. Diabetes Res Clin Pract 1995; 28 Suppl: 449-55.

10. UKPDS Group. United Kingdom Prospective Diabetes Study 7: Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 1990; 39(9): 905-12.

11. UKPDS Group. United Kingdom Prospective Diabetes Study (UKPDS) XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabed Med 1994; 11(6): 534-44.

12. Gomez MB, Lucchetti Mr, Goncalvez MF, Gazzola H, Dimetz T, Matos H. Influence of first morning urine volume, fasting blood glucose and glycosylated hemoglobin on first morning urinary albumin concentration. Braz J Med Biol Res 1997; 30(2): 191-196.

13. Rodríguez MM, Guerrero RJ. Estudio comparativo de pacientes con diabetes tipo 2, habitantes de comunidades urbanas y rurales. Rev Med IMSS 1998; 36(3): 191-197.

14. American Diabetes Association: Clinical practice recommendation 1999. Diabetes Care 1999; Suppl 1: 91-114.

15. Revilla MM, Areola F, Castro MG, Escobedo PJ, Fiorelli S, Gutiérrez C y cols. Pruebas de laboratorio útiles para el control de la diabetes mellitus. Hemoglobina glucosilada. Rev Med IMSS 1995; 33(5): 501-504.

16. Rybka J. Evidence of the value of good compensation in diabetes. Vnitr Lek 1994; 40(5): 313-5.

17. Testa R, Testa I, Manfrini S, Bonfigli AR, Piantanelli L, Marra M, Pieri C. Glycosylated hemoglobin and fructosamines: does their determination really reflect the glycemic control in diabetic patients? Life Sci 1996; 59(1): 43-9.

18. Mehra IV. Strategies of the treatment of type II diabetes mellitus. Pharm pract manag Q 1997; 17(2): 1-11.

19. Bustos-Saldaña R, Solís-Ruiz M, Torres-Ventura G, Beas-Roque S. Una glucemia de ayuno en el control metabólico crónico del paciente diabético. Arch Med Fam 2000; 2(2): 53-58.

20. Bustos-Saldaña R, González-Ortiz M, Martínez AE, Solís-Ruiz M. Sensibilidad y especificidad de una glucemia de ayuno ocasional normal en el control crónico del paciente diabético tipo 2. Revista Boliviana de Medicina Familiar 2004; julio-Diciembre: (en prensa).

21. Abrahamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose context. Arch Intern Med 2004; 164(5): 486-91.

22. Aguilar-Salinas CA, Monroy OV, Gómez-Pérez FJ, Chávez AG, Esqueda AL, Cuevas VM, Rull-Rodrigo JA, Conyer RT. Characteristics of patients with Type 2 diabetes mellitus in Mexico. Results from a large population–based nationwide survey. Diabetes Care 2003; 26(7): 20021-26.

23. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003; 163(11): 1306-16.

24. El-Kebbi IM, Ziemmer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 2004; 27(2): 335-39.

25. García NR, Rodríguez MR, Munguía MC, Hernández SJ, Casas TE, Martínez BM, Cabrera RM. Comparación de la glucemia de ayuno y dos horas postprandial en el control de los pacientes con diabetes mellitus tipo 2. Revista de Investigación Clínica 2003; 55(1): 26-30.